サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1643920

グルテン不耐症治療の世界市場（2025年～2032年）

Global Gluten Intolerance Treatment Market - 2025-2032

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
グルテン不耐症治療の世界市場（2025年～2032年）
出版日: 2025年01月27日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のグルテン不耐症治療の市場規模は、2024年に66億3,000万米ドルに達し、2032年には161億8,000万米ドルに達すると予測され、予測期間2024年～2032年のCAGRは11.8％で成長する見通しです。

グルテン不耐症は、非セリアック・グルテン過敏症としても知られ、セリアック病や小麦アレルギーがなくても、グルテンを含む食品を摂取した後に腹部不快感、腹部膨満感、疲労感などの症状が現れる疾患です。セリアック病とは異なり、グルテン不耐症は小腸にダメージを与えることはありませんが、それでも大きな不快感を引き起こし、生活の質に影響を与える可能性があります。

グルテン不耐症治療市場には、栄養補助食品、酵素療法、新たな医薬品など、症状の緩和や消化の改善を目的とした治療が含まれます。グルテン不耐症とその症状についてより多くの人々が認識するようになるにつれ、支持的治療と管理ソリューションの市場は拡大しています。

市場力学：

促進要因と抑制要因

グルテン不耐症の診断率の増加

診断率の増加は、医療介入を求める患者数の増加につながり、グルテン不耐症治療市場を牽引するとみられます。グルテン不耐症やセリアック病に対する認識が医療従事者や一般市民の間で高まるにつれ、正確に診断される患者が増えています。このような診断の増加は、酵素療法、サプリメント、新たな薬物療法などの効果的な治療オプションに対する需要の増加につながります。

さらに、グルテン抜きの厳格な食事療法だけでなく、自分の症状を管理するための解決策を積極的に求める診断者が増えており、支持療法市場に拍車をかけています。グルテン不耐症と診断される症例数が増え続けるにつれ、グルテン不耐症治療市場は大幅に拡大するとみられます。

食事嗜好と非医学的アプローチ

食事嗜好と非医学的アプローチは、グルテン不耐症治療市場の妨げになると予想されます。グルテンフリーの食事は、症状をコントロールするための主要かつ最も効果的な方法であると広く考えられているため、多くの患者は酵素サプリメントや薬物療法などの追加治療を求める傾向が低いです。このような食事管理への依存は、医療療法の市場需要を制限します。

さらに、生活習慣の改善など非医療的なアプローチで十分と考える患者もいるため、新たな治療法に対する緊急性が低下し、市場成長が鈍化する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • グルテン不耐症の診断率増加
    • 抑制要因
      • 食事嗜好と非医学的アプローチ
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析
  • SWOT分析
  • アンメットニーズ

第6章 治療タイプ別

  • 食事管理
  • 医薬品
  • 栄養補助食品
  • その他

第7章 エンドユーザー別

  • 小児
  • 成人
  • 高齢者

第8章 処方別

  • 錠剤
  • 粉末
  • 液体

第9章 流通チャネル別

  • オンライン薬局
  • 小売薬局
  • eコマース

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • DSM-Firmenich
    • 会社概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 実績および予測の製品販売
      • 製品販売量
    • 財務概要
      • 企業収益
      • 地域別収益シェア
      • 収益予測
    • 主な発展
      • 合併と買収
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Genetic Nutrition
  • NOW Foods
  • Enzymedica
  • AMYRA Biotech AG
  • KLAIRE LABS
  • Precigen
  • Takeda Pharmaceutical Company Limited

第13章 付録

目次
Product Code: PH9054

The global gluten intolerance treatment market reached US$ 6.63 billion in 2024 and is expected to reach US$ 16.18 billion by 2032, growing at a CAGR of 11.8% during the forecast period 2024-2032.

Gluten intolerance, also known as non-celiac gluten sensitivity, is a condition where individuals experience symptoms such as abdominal discomfort, bloating, and fatigue after consuming gluten-containing foods, without having celiac disease or a wheat allergy. Unlike celiac disease, gluten intolerance does not cause damage to the small intestine but can still lead to significant discomfort and impact quality of life.

The gluten intolerance treatment market encompasses treatments aimed at alleviating symptoms and improving digestion, including dietary supplements, enzyme therapies, and emerging pharmaceutical options. As more people become aware of gluten intolerance and its symptoms, the market for supportive treatments and management solutions is expanding.

Market Dynamics: Drivers & Restraints

Growing Diagnosis Rates of Gluten-intolerance

Increasing diagnosis rates are expected to drive the gluten intolerance treatment market by leading to a larger patient population seeking medical interventions. As awareness of gluten intolerance and celiac disease grows among both healthcare providers and the public, more individuals are being accurately diagnosed. This rise in diagnoses translates to greater demand for effective treatment options, such as enzyme therapies, supplements, and emerging drug therapies.

Additionally, more diagnosed individuals are actively seeking solutions to manage their condition beyond a strict gluten-free diet, fueling the market for supportive treatments. As the number of diagnosed cases continues to rise, the market for gluten intolerance treatments is likely to expand significantly.

Dietary Preferences and Non-Medical Approaches

Dietary preferences and non-medical approaches are expected to hinder the gluten intolerance treatment market as many individuals prefer managing their condition through a gluten-free diet rather than relying on pharmaceutical interventions. The gluten-free diet is widely considered the primary and most effective way to control symptoms, which makes many patients less inclined to seek additional treatments such as enzyme supplements or medications. This reliance on dietary management limits the market demand for medical therapies.

Additionally, individuals may feel that non-medical approaches, such as lifestyle changes, are sufficient to manage their condition, reducing the urgency for new treatments and thus slowing market growth.

Segment Analysis

The global gluten intolerance treatment market is segmented based on treatment type, patient type, formulation, distribution channel, and region.

Type:

Nutritional supplements segment is expected to dominate the global gluten intolerance treatment market share

Nutritional supplements are expected to dominate the gluten intolerance treatment market due to their accessibility and growing popularity among patients seeking to manage symptoms alongside a gluten-free diet. Products like enzyme supplements and probiotics are gaining traction as they offer a convenient, non-invasive option to alleviate discomfort from accidental gluten exposure. Companies are focusing on developing these products which are increasingly gaining traction due to their increased safety and efficacy. For instance, in October 2024, AMYRA Biotech AG announced the peer-reviewed publication of its clinical proof-of-principle study with its lead product AMYNOPEP. AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical endogenous enzymes on the lining of the small intestine.

With increasing consumer awareness of the benefits of such supplements, the demand for these products is expanding, as they provide additional support without the need for prescription drugs. This trend positions nutritional supplements as a key segment in the market, driven by their ability to offer symptom relief and improve overall gut health for individuals with gluten intolerance.

Geographical Analysis

North America is expected to hold a significant position in the global gluten intolerance treatment market share

North America is expected to dominate the gluten intolerance treatment market due to high awareness, advanced healthcare infrastructure, and a large consumer base actively seeking treatment options. The U.S., in particular, leads in both diagnosis rates and adoption of gluten intolerance treatments, with a growing number of patients opting for enzyme supplements and emerging therapies.

Additionally, the presence of key pharmaceutical companies and the increasing availability of gluten-free products and treatments further strengthen North America's market share. The rising expansion of product availability in the region with rising innovative products is expected to contribute to the market growth in the region. For instance, in December 2024 GluteGuard, the first and only clinically proven product in Canada that helps to protect against the symptoms of accidental gluten ingestion is made available across the country. With the expansion of product expansion in the region, the market is expected to grow which contributes to the overall market growth. As awareness of gluten intolerance continues to rise, the region is likely to maintain its dominance in the treatment market.

Competitive Landscape

The major global players in the gluten intolerance treatment market include DSM-Firmenich, Genetic Nutrition, NOW Foods, Enzymedica, AMYRA Biotech AG, KLAIRE LABS, Precigen and Takeda Pharmaceutical Company Limited among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Gluten Intolerance Treatment Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Patient Type
  • 3.3. Snippet by Formulation
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Diagnosis Rates of Gluten-intolerance
    • 4.1.2. Restraints
      • 4.1.2.1. Dietary Preferences and Non-Medical Approaches
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Dietary Management*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Pharmaceuticals
  • 6.4. Nutritional Supplements
  • 6.5. Others

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Pediatric*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Adult
  • 7.4. Geriatric

8. By Formulation

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 8.1.2. Market Attractiveness Index, By Formulation
  • 8.2. Tablets*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Powders
  • 8.4. Liquid

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Online Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. E-Commerce

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Formulation
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. DSM-Firmenich*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Genetic Nutrition
  • 12.3. NOW Foods
  • 12.4. Enzymedica
  • 12.5. AMYRA Biotech AG
  • 12.6. KLAIRE LABS
  • 12.7. Precigen
  • 12.8. Takeda Pharmaceutical Company Limited
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us